Information on the target
Philip Morris International (PMI) is a leading company in the field of smoke-free tobacco products and is the only firm to have received authorizations for heated tobacco products classified as Modified Risk Tobacco Products (MRTP). The U.S. Food and Drug Administration (FDA) has concluded that scientific studies demonstrate a significant reduction in exposure to harmful or potentially harmful chemicals when transitioning completely from conventional cigarettes to the IQOS system. This innovative approach positions PMI at the forefront of the tobacco industry’s shift towards less harmful alternatives.
On April 17, 2026, the FDA announced the renewal of marketing orders for two versions of the IQOS device and three variants of HEETS tobacco sticks, allowing PMI to continue sharing information about reduced exposure with U.S. adults aged 21 and older who use traditional tobacco products. The FDA's decision reflects a commitment to public health and is expected to benefit the overall health of the population, including both tobacco users and non-users.
Industry overview in the target’s specific country
The U.S. tobacco industry is undergoing a significant transformation as consumer preferences shift towards reduced-risk products. With approximately 45 million legal nicotine consumers in the United States, around 25 million of whom still smoke traditional cigarettes, the demand for smoke-free alternatives is rising. The FDA's regulatory framework has evolved to accommodate these changes, allowing for the introduction and marketing of innovative products that aim to reduce the health risks associated with smoking.
Heated tobacco products, such as IQOS, represent a growing segment within this industry. By heating tobacco instead of burning it, these products significantly reduce the formation of harmful chemicals typically generated through combustion. This shift not only caters to health-conscious consumers but also aligns with regulatory efforts to promote public health. The FDA's endorsement of IQOS as a modified risk product underscores the scientific backing that supports its reduced-risk claims.
Moreover, the competitive landscape is becoming increasingly dynamic, with established tobacco companies and new entrants vying for market share in the smoke-free category. PMI's substantial investments in research and development, exceeding $16 billion since 2008, highlight its commitment to innovation and its strategic focus on transitioning smokers to less harmful alternatives. This investment is crucial as the company aims to phase out traditional cigarette sales entirely.
As regulatory policies continue to evolve, they will play a pivotal role in shaping the future of the tobacco industry. The FDA's recent actions signal a willingness to support products that demonstrate a potential for r…